Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, BridgeBio Oncology Therapeutics Inc. (BBOT) has a Wall Street consensus price target of $23.33, based on estimates from 2 covering analysts. With the stock currently trading at $10.03, this represents a potential upside of +132.6%. The company has a market capitalization of $794M.
Analyst price targets range from a low of $18.00 to a high of $27.00, representing a 39% spread in expectations. The median target of $23.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BBOT trades at a trailing P/E of 21.8x. Analysts expect EPS to grow +60.1% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BBOT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for BBOT is $23.33, representing 132.6% upside from the current price of $10.03. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BBOT has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $23.33 implies 132.6% upside from current levels.
BBOT's current price is $10.03 with a consensus target of $23.33 (132.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $27 for BBOT, while the most conservative target is $18. The consensus of $23.33 represents the median expectation. These targets typically reflect 12-month expectations.
BBOT is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BBOT stock forecast based on 2 Wall Street analysts shows a consensus price target of $23.33, with estimates ranging from $18 (bear case) to $27 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BBOT, with a "Buy" consensus rating and $23.33 price target (132.6% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BBOT analyst price targets range from $18 to $27, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $23.33 consensus represents the middle ground.